Table 2.

In vivo activities of isavuconazole against C. albicans, C. tropicalis, and C. glabrata in a neutropenic disseminated candidiasis model

Speciesa	Isolate	Treatment duration (h)	ED50 (mg/kg/12 h)	MIC (mg/liter)b	24-h AUC/MIC ratio
					Total drug	Free drug
C. albicans	580	96	65.6	0.008	5,983	59.8
	98-210		30.7	0.03	306	3.1
	2183		58.5	0.008	4,787	47.9
	98-17		83.7	0.031	2,258	22.6
Mean ± SD, 96-h treatment					3,334 ± 2,546	33.4 ± 25.4
	580	24	85.5	0.008	9,335	93.4
	2183		89.7	0.008	10,043	100
	98-17		148	0.03	4,966	49.7
	K1		33.8	0.004	2,747	27.5
Mean ± SD, 24-h treatment					6,773 ± 3,499	67.7 ± 34.9
Mean ± SD, all C. albicans isolates					5,053 ± 3,377	50.5 ± 33.7
C. tropicalis	98-234	24	31.2	0.016	624	6.2
C. glabrata	14378	96	52.6	0.25	119	1.2
	35315		48.4	0.125	193	1.9
Mean ± SD, non-C. albicans isolates					312 ± 273	3.1 ± 2.7

^aP, 0.04 for comparison of means between all C. albicans species and non-albicans Candida species.

^bDetermined by the CLSI method.